FTDZX: Franklin Biotechnology Discovery Fund - MutualFunds.com

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Franklin Biotechnology Discovery Adv

FTDZX - Snapshot

Vitals

  • YTD Return 16.0%
  • 3 Yr Annualized Return 8.2%
  • 5 Yr Annualized Return 7.8%
  • Net Assets $1.42 B
  • Holdings in Top 10 50.0%

52 WEEK LOW AND HIGH

$182.56
$116.20
$191.88

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.78%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 32.92%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $100,000
  • IRA N/A

Fund Classification


Compare FTDZX to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

$216.98

-0.95%

$48.66 B

1.11%

$2.43

4.21%

0.32%

$106.62

-1.11%

$23.72 B

1.43%

$1.54

3.96%

0.13%

$95.54

-0.91%

$15.31 B

0.05%

$0.05

17.33%

0.76%

$103.80

-1.09%

$13.24 B

1.72%

$1.81

8.18%

0.10%

$207.48

-1.13%

$13.24 B

1.72%

$3.62

7.74%

0.10%

FTDZX - Profile

Distributions

  • YTD Total Return 16.0%
  • 3 Yr Annualized Total Return 8.2%
  • 5 Yr Annualized Total Return 7.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.24%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 01, 2009
  • Shares Outstanding
    1184230
  • Share Class
    Adv
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Fund Description

Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.


FTDZX - Performance

Return Ranking - Trailing

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
YTD 16.0% -7.5% 106.2% 27.16%
1 Yr 49.2% 8.3% 128.7% 6.83%
3 Yr 8.2%* 0.1% 38.7% 79.72%
5 Yr 7.8%* 0.4% 30.0% 80.58%
10 Yr 17.2%* 8.9% 20.1% 29.27%

* Annualized

Return Ranking - Calendar

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
2019 23.9% 3.8% 63.8% 29.66%
2018 -18.3% -49.7% 21.5% 90.51%
2017 16.3% -59.8% 54.4% 57.04%
2016 -20.7% -36.6% 11.6% 77.52%
2015 -2.6% -62.4% 27.9% 64.75%

Total Return Ranking - Trailing

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
YTD 16.0% -7.5% 109.2% 27.16%
1 Yr 49.2% 2.7% 128.7% 6.21%
3 Yr 8.2%* 0.1% 38.7% 77.62%
5 Yr 7.8%* 0.4% 30.0% 76.26%
10 Yr 17.2%* 8.9% 20.1% 28.46%

* Annualized

Total Return Ranking - Calendar

Period FTDZX Return Category Return Low Category Return High Rank in Category (%)
2019 23.9% 3.8% 63.8% 29.66%
2018 -18.3% -25.3% 22.2% 91.97%
2017 19.1% -10.8% 54.4% 58.52%
2016 -16.9% -36.6% 11.6% 71.32%
2015 6.0% -16.6% 27.9% 49.18%

NAV & Total Return History


FTDZX - Holdings

Concentration Analysis

FTDZX Category Low Category High FTDZX % Rank
Net Assets 1.42 B 2.6 M 48.7 B 42.20%
Number of Holdings 97 26 431 44.51%
Net Assets in Top 10 710 M 670 K 18.8 B 25.43%
Weighting of Top 10 50.02% 13.2% 76.3% 17.92%

Top 10 Holdings

  1. Franklin IFT Money Market 9.85%
  2. Regeneron Pharmaceuticals Inc 6.91%
  3. Vertex Pharmaceuticals Inc 6.58%
  4. Regeneron Pharmaceuticals Inc 6.06%
  5. Regeneron Pharmaceuticals Inc 6.06%
  6. Regeneron Pharmaceuticals Inc 6.06%
  7. Regeneron Pharmaceuticals Inc 6.06%
  8. Regeneron Pharmaceuticals Inc 6.06%
  9. Amgen Inc 5.71%
  10. Gilead Sciences Inc 5.04%

Asset Allocation

Weighting Return Low Return High FTDZX % Rank
Stocks
91.72% 61.47% 100.59% 92.49%
Cash
7.41% -0.68% 32.46% 5.20%
Other
0.87% -3.06% 6.07% 21.39%
Preferred Stocks
0.00% 0.00% 6.63% 60.69%
Convertible Bonds
0.00% 0.00% 0.03% 52.60%
Bonds
0.00% 0.00% 16.11% 54.34%

Stock Sector Breakdown

Weighting Return Low Return High FTDZX % Rank
Healthcare
98.70% 61.81% 100.00% 75.72%
Financial Services
1.30% 0.00% 2.72% 2.89%
Utilities
0.00% 0.00% 0.00% 51.45%
Technology
0.00% 0.00% 20.28% 58.96%
Real Estate
0.00% 0.00% 6.03% 56.07%
Industrials
0.00% 0.00% 6.39% 55.49%
Energy
0.00% 0.00% 0.00% 51.45%
Communication Services
0.00% 0.00% 3.21% 53.76%
Consumer Defense
0.00% 0.00% 34.31% 56.07%
Consumer Cyclical
0.00% 0.00% 1.21% 57.23%
Basic Materials
0.00% 0.00% 2.61% 67.63%

Stock Geographic Breakdown

Weighting Return Low Return High FTDZX % Rank
US
81.41% 47.91% 100.00% 43.93%
Non US
10.31% 0.00% 43.87% 69.94%

FTDZX - Expenses

Operational Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.78% 0.08% 25.14% 68.67%
Management Fee 0.60% 0.00% 1.25% 35.84%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.40% 67.50%

Sales Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% 50.00%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FTDZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 32.92% 0.70% 252.00% 39.02%

FTDZX - Distributions

Dividend Yield Analysis

FTDZX Category Low Category High FTDZX % Rank
Dividend Yield 0.00% 0.00% 3.15% 61.27%

Dividend Distribution Analysis

FTDZX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

FTDZX Category Low Category High FTDZX % Rank
Net Income Ratio -0.24% -2.53% 2.53% 63.47%

Capital Gain Distribution Analysis

FTDZX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

FTDZX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

23.06

23.1%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

2.08

2.1%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

0.68

0.7%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.08 23.06 7.22 20.43